Shanmuga Hospital Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 10039550,
    "name": "Shanmuga Hos.",
    "stock_name": "Shanmuga Hos.",
    "full_name": "Shanmuga Hospital Ltd",
    "name_url": "stocks-analysis/shanmuga-hos",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "40.80",
    "chg": 2.3,
    "chgp": "5.97%",
    "dir": 1,
    "prev_price": "38.50",
    "mcapval": "53.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 544365,
    "symbol": "",
    "ind_name": "Hospital",
    "ind_code": 94,
    "indexname": "",
    "isin": "INE0TD301017",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": 12000,
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/shanmuga-hos-10039550-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Shanmuga Hos. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-shanmuga-hos-overvalued-or-undervalued-3732786",
        "imagepath": "",
        "date": "2025-11-27 08:51:17",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Understanding Shanmuga Hospitals’ Valuation Metrics</strong></p>\n<p>Shanmuga Hospitals’ price-to-earnings (PE) ratio stands at 15.44, which is considerably lower than many of its industry peers. For instance, Max Healthcare and Fortis Healthcare exhibit PE ratios well above 70, while Apollo Hospitals, considered an attractive valuation, trades at a PE of around 63.6. This relatively modest PE ratio indicates that Shanmuga Hospitals is priced more conservatively in terms of earnings compared to the broader hospital sector.</p>\n<p>Its price-to-book (P/B) ratio of 1.56 also suggests that the stock is trading at a slight premium to its book value, but not excessively so. This contrasts with some peers whose valuations imply a much higher premium, reflecting either stronger growth expectations or..."
      },
      {
        "title": "Is Shanmuga Hos. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-shanmuga-hos-overvalued-or-undervalued-3716826",
        "imagepath": "",
        "date": "2025-11-20 08:08:34",
        "description": "As of 19 November 2025, the valuation grade for Shanmuga Hospitals has moved from very attractive to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios include a PE ratio of 14.42, an EV to EBITDA of 8.10, and a ROCE of 12.75%. \n\nIn comparison to its peers, Shanmuga Hospitals' PE ratio is significantly lower than that of Max Healthcare, which stands at 80.06, and also lower than Apollo Hospitals at 64.09. This suggests that while Shanmuga is overvalued, it is still more attractively priced than some of its competitors. Despite a recent one-week stock return of 4.57% compared to the Sensex's 0.85%, the overall valuation metrics indicate that investors should approach Shanmuga Hospitals with caution...."
      },
      {
        "title": "How has been the historical performance of Shanmuga Hos.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-shanmuga-hos-3695900",
        "imagepath": "",
        "date": "2025-11-13 00:44:41",
        "description": "Answer:\nThe historical performance of Shanmuga Hos. shows a steady increase in net sales over the past three years, rising from 39.34 Cr in Mar'23 to 43.04 Cr in Mar'24, and reaching 47.85 Cr in Mar'25. The total operating income mirrored this trend, with a consistent increase to 47.85 Cr in Mar'25. However, the operating profit (PBDIT) has seen a slight decline from 8.95 Cr in Mar'24 to 8.47 Cr in Mar'25, despite an increase in other income. Profit before tax also decreased from 7.02 Cr in Mar'24 to 5.69 Cr in Mar'25, leading to a profit after tax of 4.21 Cr in Mar'25, down from 5.25 Cr in Mar'24. The earnings per share (EPS) reflected this decline, dropping to 3.09 in Mar'25 from 5.36 in Mar'24. On the balance sheet, total assets increased significantly from 33.92 Cr in Mar'24 to 52.78 Cr in Mar'25, driven by a rise in cash and bank balances and total reserves. Total liabilities also rose, but at a slower..."
      }
    ],
    "total": 73,
    "sid": "10039550",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/shanmuga-hospital-10039550"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "09-Jan-2026",
      "details": "Certificate pursuant to Regulation 74(5) of SEBI(DP)regulations 2018 for the period from 01.10.2025 to 31.12.2025",
      "source": "BSE"
    },
    {
      "caption": "Intimation Regarding Commissioning And Operationalisation Of Litho Evo Laser Machine",
      "datetime": "09-Jan-2026",
      "details": "Intimation regarding Commissioning and Operationalisation of Litho Evo Laser Machine",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
      "datetime": "28-Nov-2025",
      "details": "Investor Presentation under Regulation 30 read with Schedule III of SEBI(LODR) 2015",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Shanmuga Hos. overvalued or undervalued?

2025-11-27 08:51:17

Understanding Shanmuga Hospitals’ Valuation Metrics Shanmuga Hospitals’ price-to-earnings (PE) ratio stands at 15.44, which is considerably lower than many of its industry peers. For instance, Max Healthcare and Fortis Healthcare exhibit PE ratios well above 70, while Apollo Hospitals, considered an attractive valuation, trades at a PE of around 63.6. This relatively modest PE ratio indicates that Shanmuga Hospitals is priced more conservatively in terms of earnings compared to the broader hospital sector. Its price-to-book (P/B) ratio of 1.56 also suggests that the stock is trading at a slight premium to its book value, but not excessively so. This contrasts with some peers whose valuations imply a much higher premium, reflecting either stronger growth expectations or...

Is Shanmuga Hos. overvalued or undervalued?

2025-11-20 08:08:34

As of 19 November 2025, the valuation grade for Shanmuga Hospitals has moved from very attractive to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued. Key ratios include a PE ratio of 14.42, an EV to EBITDA of 8.10, and a ROCE of 12.75%. In comparison to its peers, Shanmuga Hospitals' PE ratio is significantly lower than that of Max Healthcare, which stands at 80.06, and also lower than Apollo Hospitals at 64.09. This suggests that while Shanmuga is overvalued, it is still more attractively priced than some of its competitors. Despite a recent one-week stock return of 4.57% compared to the Sensex's 0.85%, the overall valuation metrics indicate that investors should approach Shanmuga Hospitals with caution....

How has been the historical performance of Shanmuga Hos.?

2025-11-13 00:44:41

Answer: The historical performance of Shanmuga Hos. shows a steady increase in net sales over the past three years, rising from 39.34 Cr in Mar'23 to 43.04 Cr in Mar'24, and reaching 47.85 Cr in Mar'25. The total operating income mirrored this trend, with a consistent increase to 47.85 Cr in Mar'25. However, the operating profit (PBDIT) has seen a slight decline from 8.95 Cr in Mar'24 to 8.47 Cr in Mar'25, despite an increase in other income. Profit before tax also decreased from 7.02 Cr in Mar'24 to 5.69 Cr in Mar'25, leading to a profit after tax of 4.21 Cr in Mar'25, down from 5.25 Cr in Mar'24. The earnings per share (EPS) reflected this decline, dropping to 3.09 in Mar'25 from 5.36 in Mar'24. On the balance sheet, total assets increased significantly from 33.92 Cr in Mar'24 to 52.78 Cr in Mar'25, driven by a rise in cash and bank balances and total reserves. Total liabilities also rose, but at a slower...

View All News